Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
Novo Eyes Longevity
Description
Novo Nordisk said future GLP-1 medicines could expand beyond obesity and diabetes into areas like heart, kidney, skincare, and hair-loss treatments.
More from User
01:03
Novo Eyes Longevity
Benzinga
00:58
Goldman Shifts Rate Outlook
Benzinga
01:04
Dems Urge Relief
Benzinga
00:55
Nvidia's AI Chip Bet
Benzinga
00:48
Meta Stock Drops 5%
Benzinga
00:56
Airlines Face Profit Drop
Benzinga
Related Videos
01:52
Ten Pharma Firms Form Non-profit to Speed Up New Drug Trials; InBalance Health Launches New Nutrition Bars; Novo Nordisk Ranks High on Carbon Disclosure Project - Health Minute for September 27, 2012
3BL Media
00:38
'Stop Ripping Us Off.' Senate Grills Novo Nordisk on High Prices of Weight Loss Drugs Wegovy and Ozempic in US.
Benzinga
00:48
Novo Nordisk Shares Jump After CEO Predicts Wegovy Recovery as Compounded Drugs Exit U.S. Market
Benzinga
01:09
Why Novo Nordisk Stock Is Down (NVO)
Benzinga
00:37
Novo Nordisk Launches First GLP-1 Weight Pill
Cheddar News
01:36
Novo Nordisk sues Hims and Hers over "blatant rip-off" GLP-1 pill
Straight Arrow News